Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model

Oncotarget

Volumn 5, Issue 3, 2014, Pages 634-648

  Siveen, Kodappully Sivaraman ^a   Mustafa, Nurulhuda ^b,c   Li, Feng ^a   Kannaiyan, Radhamani ^a   Ahn, Kwang Seok ^d   Kumar, Alan Prem ^a,b,e,f   Chng, Wee Joo ^b,c   Sethi, Gautam ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d Kyung Hee University   (South Korea)

^e CURTIN UNIVERSITY   (Australia)

^f UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Apoptosis; Bortezomib; MM; NF B; Thymoquinone

Indexed keywords

BORTEZOMIB; CASPASE 3; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; DOXORUBICIN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; KI 67 ANTIGEN; MELPHALAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; SYNDECAN 1; THYMOQUINONE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BCL 2 GENE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; COX2 GENE; CXCR4 GENE; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE DISRUPTION; GENE PRODUCT; HUMAN; HUMAN CELL; IL 6 GENE; IN VITRO STUDY; IN VIVO STUDY; KI 67 GENE; MALE; MIGRATION INHIBITION; MMP9 GENE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; P65 GENE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TNFALPHA GENE; TUMOR INVASION; TUMOR XENOGRAFT; VEGF GENE; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZOQUINONES; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIPLE MYELOMA; NF-KAPPA B; PYRAZINES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896852179     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1596     Document Type: Article

References (48)

1. Mirandola L, Yu Y, Chui K, Jenkins MR, Cobos E, John CM and Chiriva-Internati M. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PloS one. 2011; 6(7):e21811.
2. Kuehl WM and Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. The Journal of clinical investigation. 2012; 122(10):3456.
3. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ and Baris D. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 2009; 113(22):5412-5417.
4. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF and Fonseca R. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. New England Journal of Medicine. 2007; 356(25):2582-2590.
5. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians. 2013; 63(1):11-30.
6. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol. 2011; 8(8):479-491.
7. Kortuem KM and Stewart AK. Carfilzomib. Blood. 2013; 121(6):893-897.
8. Elkinson S and McCormack PL. Pomalidomide: First Global Approval. Drugs. 2013:1-10.
9. Podar K, Tai Y-T, Hideshima T, Vallet S, Richardson PG and Anderson KC. Emerging therapies for multiple myeloma. 2009.
10. Rossi J. Chemoresistance and multiple myeloma: from biological to clinical aspects. Stem cells (Dayton, Ohio). 1995; 13:64.
11. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S and Aggarwal BB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-κB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007; 109(6):2293-2302.
12. Li F, Rajendran P and Sethi G. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. British journal of pharmacology. 2010;161(3):541-554.
13. Seitz CS, Lin Q, Deng H and Khavari PA. Alterations in NF-κB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-κB. Proceedings of the National Academy of Sciences. 1998; 95(5):2307-2312.
14. Sethi G and Tergaonkar V. Potential pharmacological control of the NF-kappaB pathway. Trends in pharmacological sciences. 2009; 30(6):313-321.
15. Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S and Aggarwal BB. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther. 2009; 8(4):959-970.
16. Woo CC, Kumar AP, Sethi G and Tan KH. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochemical pharmacology. 2012; 83(4):443-451.
17. Sethi G, Ahn KS and Aggarwal BB. Targeting Nuclear Factor-κB Activation Pathway by Thymoquinone: Role in Suppression of Antiapoptotic Gene Products and Enhancement of Apoptosis. Molecular Cancer Research. 2008; 6(6):1059-1070.
18. Woo CC, Hsu A, Kumar AP, Sethi G and Tan KH. Thymoquinone Inhibits Tumor Growth and Induces Apoptosis in a Breast Cancer Xenograft Mouse Model: The Role of p38 MAPK and ROS. PloS one. 2013; 8(10):e75356.
19. Demchenko YN and Kuehl WM. A critical role for the NFkB pathway in multiple myeloma. Oncotarget. 2010; 1(1):59.
20. Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Chng WJ and Sethi G. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol. 2011; 164(5):1506-1521.
21. Li Z-W, Chen H, Campbell RA, Bonavida B and Berenson JR. NF-κB in the pathogenesis and treatment of multiple myeloma. Current Opinion in Hematology. 2008; 15(4):391-399 310.1097/MOH.1090b1013e328302c32830 7f328304.
22. Manu KA, Shanmugam MK, Ramachandran L, Li F, Fong CW, Kumar AP, Tan P and Sethi G. First evidence that γ-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-κB pathway. Clinical Cancer Research. 2012; 18(8):2220-2229.
23. van de Donk NW, Bloem AC and Lokhorst HM. New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway. Current pharmaceutical design. 2006; 12(3):327-340.
24. Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A, Lam P, Kumar AP and Sethi G. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis: an international journal on programmed cell death. 2011; 16(10):1028-1041.
25. Agarwal A and Ghobrial IM. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor Disease. Clinical Cancer Research. 2012.
26. Hideshima T, Podar K, Chauhan D and Anderson KC. Cytokines and signal transduction. Best Practice & Research Clinical Haematology. 2005; 18(4):509-524.
27. Burger JA and Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006; 107(5):1761-1767.
28. Möller C, Strömberg T, Juremalm M, Nilsson K and Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia. 2003; 17(1):203-210.
29. Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N and Anderson KC. The Biological Sequelae of Stromal Cell-derived Factor-1α in Multiple Myeloma 1 This work was supported by Multiple Myeloma Research Foundation Senior Awards (to T. H. and D. C.), Leukemia and Lymphoma Society Scholar Award (to N. M.), NIH Grant PO-1 78378, and the Doris Duke Distinguished Clinical Research Scientist Award (to K. A.).1. Molecular Cancer Therapeutics. 2002; 1(7):539-544.
30. Rodríguez D, Morrison CJ and Overall CM. Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2010; 1803(1):39-54.
31. Zdzisińska B, Walter-Croneck A, Dmoszyńska A and Kandefer-Szerszeń M. Matrix metalloproteinase and cytokine production by bone marrow adherent cells from multiple myeloma patients. Archivum immunologiae et therapiae experimentalis. 2006; 54(4):289-296.
32. Broek IV, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, Van Camp B and Van Riet I. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia. 2004; 18(5):976-982.
33. Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S, Devy L, Noël A, De Bruyne E and Asosingh K. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. The American journal of pathology. 2004; 165(3):869-878.
34. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL and Kuehl WM. Classical and/or alternative NF-κB pathway activation in multiple myeloma. Blood. 2010; 115(17):3541-3552.
35. Berenson JR, Ma HM and Vescio R. (2001). The role of nuclear factor-κB in the biology and treatment of multiple myeloma. Seminars in oncology: Elsevier), pp. 626-633.
36. Baumann P, Mandl-Weber S, Oduncu F and Schmidmaier R. Alkylating agents induce activation of NFκB in multiple myeloma cells. Leukemia research. 2008; 32(7):1144-1147.
37. Takahashi H and Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clinical Science. 2005; 109:227-241.
38. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Journal of clinical oncology. 2002; 20(21):4368-4380.
39. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S and Keating M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000; 96(6):2240-2245.
40. Salven P, Orpana A, Teerenhovi L and Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood. 2000; 96(12):3712-3718.
41. Bellamy WT. (2001). Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Seminars in oncology: Elsevier), pp. 551-559.
42. Molica S, Vitelli G, Levato D, Gandolfo GM and Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. British journal of haematology. 1999; 107(3):605-610.
43. Feinman R, Koury J, Thames M, Barlogie B, Epstein J and Siegel DS. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood. 1999; 93(9):3044-3052.
44. Guo Y, Xu F, Lu T, Duan Z and Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer treatment reviews. 2012; 38(7):904-910.
45. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D and Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993; 82(12):3712-3720.
46. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. The FASEB Journal. 1999; 13(1):9-22.
47. Jöhrer K, Janke K, Krugmann J, Fiegl M and Greil R. Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-α via TNF receptor 2 and autocrine up-regulation of MCP-1. Clinical cancer research. 2004; 10(6):1901-1910.
48. Bartlett JB, Dredge K and Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Reviews Cancer. 2004; 4(4):314-322.